Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.

Middleton D, Diler AS, Meenagh A, Sleator C, Gourraud PA.

Tissue Antigens. 2009 Jun;73(6):553-60. doi: 10.1111/j.1399-0039.2009.01235.x.

PMID:
19493232
2.

Combination of KIR 2DL2 and HLA-C1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians.

Shastry A, Sedimbi SK, Rajalingam R, Nikitina-Zake L, Rumba I, Wigzell H, Sanjeevi CB.

Int J Immunogenet. 2008 Dec;35(6):439-46. doi: 10.1111/j.1744-313X.2008.00804.x.

PMID:
19046302
3.

Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.

Gao X, Jiao Y, Wang L, Liu X, Sun W, Cui B, Chen Z, Zhao Y.

Clin Immunol. 2010 Oct;137(1):139-46. doi: 10.1016/j.clim.2010.05.011.

PMID:
20643584
4.

KIR2DS3 is associated with protection against acute myeloid leukemia.

Shahsavar F, Tajik N, Entezami KZ, Fallah Radjabzadeh M, Asadifar B, Alimoghaddam K, Ostadali Dahaghi M, Jalali A, Ghashghaie A, Ghavamzadeh A.

Iran J Immunol. 2010 Mar;7(1):8-17. doi: IJIv7i1A2.

5.

Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis.

Lorentzen AR, Karlsen TH, Olsson M, Smestad C, Mero IL, Woldseth B, Sun JY, Senitzer D, Celius EG, Thorsby E, Spurkland A, Lie BA, Harbo HF.

Ann Neurol. 2009 Jun;65(6):658-66. doi: 10.1002/ana.21695.

PMID:
19630074
6.

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.

Keating SE, Ní Chorcora C, Dring MM, Stallings RL, O'Meara A, Gardiner CM.

Tissue Antigens. 2015 Sep;86(3):172-7. doi: 10.1111/tan.12608. Epub 2015 Jul 22.

PMID:
26202659
7.

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.

La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, Orrù S, Orrù N, Floris A, Carcassi C.

Exp Hematol. 2013 May;41(5):424-31. doi: 10.1016/j.exphem.2013.01.008. Epub 2013 Feb 1.

PMID:
23380384
8.

Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals.

Levinson RD, Du Z, Luo L, Monnet D, Tabary T, Brezin AP, Zhao L, Gjertson DW, Holland GN, Reed EF, Cohen JH, Rajalingam R.

Genes Immun. 2008 Apr;9(3):249-58. doi: 10.1038/gene.2008.13. Epub 2008 Mar 13.

PMID:
18340360
9.

Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome.

Lowe DP, Cook MA, Bowman SJ, Briggs DC; UK Sjögren's Interest Group.

Rheumatology (Oxford). 2009 Apr;48(4):359-62. doi: 10.1093/rheumatology/ken503. Epub 2009 Jan 30.

PMID:
19181658
10.

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.

Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC.

Blood. 2004 Feb 15;103(4):1521-6. Epub 2003 Sep 22.

11.

KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population.

Wiśniewski A, Jankowska R, Passowicz-Muszyńska E, Wiśniewska E, Majorczyk E, Nowak I, Frydecka I, Kuśnierczyk P.

Hum Immunol. 2012 Sep;73(9):927-31. doi: 10.1016/j.humimm.2012.07.323. Epub 2012 Jul 23.

PMID:
22836042
12.

[Killer cell immunoglobulin receptor plays an important role in cord blood transplantation for leukemia].

Zhang X, Liu KY, Lu DP.

Zhonghua Yi Xue Za Zhi. 2006 Nov 14;86(42):2962-5. Chinese.

PMID:
17288806
13.

Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis.

Chandran V, Bull SB, Pellett FJ, Ayearst R, Pollock RA, Gladman DD.

Rheumatology (Oxford). 2014 Feb;53(2):233-9. doi: 10.1093/rheumatology/ket296. Epub 2013 Oct 31.

PMID:
24185760
14.

[Association of genetic polymorphisms of KIR-HLA system with chronic myeloid leukemia among ethnic Hans from southern China].

Deng Z, Zhen J, Wang D, He L, Zou H.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2017 Feb 10;34(1):53-57. doi: 10.3760/cma.j.issn.1003-9406.2017.01.012. Chinese.

PMID:
28186594
15.

Killer cell immunoglobulin-like receptors in Thai patients with leukemia and diffuse large B-cell lymphoma.

Vejbaesya S, Sae-Tam P, Khuhapinant A, Srinak D.

Hum Immunol. 2014 Jul;75(7):673-6. doi: 10.1016/j.humimm.2014.04.004. Epub 2014 Apr 19.

PMID:
24755352
16.

Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis.

Salim PH, Jobim M, Bredemeier M, Chies JA, Schlottfeldt J, Brenol JC, Jobim LF, Xavier RM.

Clin Exp Immunol. 2010 Jun;160(3):325-30. doi: 10.1111/j.1365-2249.2010.04095.x. Epub 2010 Jan 15.

17.

Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor.

Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW, Schwan MA, Grosse-Wilde H, Wernet P, Uhrberg M.

J Immunol. 2007 Mar 15;178(6):3918-23.

18.

Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA-C1 ligand binding.

Ramos-Lopez E, Scholten F, Aminkeng F, Wild C, Kalhes H, Seidl C, Tonn T, Van der Auwera B, Badenhoop K.

Tissue Antigens. 2009 Jun;73(6):599-603. doi: 10.1111/j.1399-0039.2009.01252.x. Epub 2009 Apr 8.

PMID:
19392800
19.

[Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].

Bao XJ, He J, Chen ZX, Wu DP, Yao L, Yuan XN, Cen JN, Qiu QC, Di WY, Zhang H, Zhang J, Zhou XH, Xu HX.

Zhonghua Xue Ye Xue Za Zhi. 2007 Aug;28(8):510-3. Chinese.

PMID:
18078124
20.

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.

van der Meer A, Schaap NP, Schattenberg AV, van Cranenbroek B, Tijssen HJ, Joosten I.

Mol Immunol. 2008 Aug;45(13):3631-8. doi: 10.1016/j.molimm.2008.04.016. Epub 2008 Jun 16.

PMID:
18555529

Supplemental Content

Support Center